Form 4: CytomX CMO Granted 75,000 RSUs, 300,000 Options

CytomX Therapeutics' Chief Medical Officer, Yu-Waye Chu, reported the acquisition of 75,000 restricted stock units and 300,000 stock options.

Summary

• Yu-Waye Chu, Chief Medical Officer of CytomX Therapeutics, Inc. (CTMX), acquired 75,000 Restricted Stock Units (RSUs) on February 2, 2026.
• Each RSU entitles the reporting person to receive one share of Common Stock upon vesting.
• The RSUs vest in three annual installments, with 1/3rd vesting on March 15, 2027, and subsequent 1/3rd portions vesting on March 15 of each following year, contingent on continued service.
• Following this transaction, the reporting person beneficially owns 210,725 shares of Common Stock, which includes 206,000 RSUs.
• Additionally, Yu-Waye Chu acquired 300,000 stock options with an exercise price of $6.09 on February 2, 2026.
• These stock options vest monthly over four years, with 1/48th vesting on each monthly anniversary from February 2, 2026, leading to full vesting on February 2, 2030, subject to continued service.
• The stock options have an expiration date of February 1, 2036.
• Following this transaction, the reporting person beneficially owns 300,000 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development for corporate governance and executive alignment, as it represents a significant equity grant tied to future performance and continued service, which is a standard practice for executive retention and motivation.

Positives

• The grant of restricted stock units and stock options aligns the Chief Medical Officer's financial interests with the long-term performance and shareholder value of CytomX Therapeutics.
• Equity compensation serves as a key mechanism for executive retention and motivation, encouraging continued service and dedication to the company's strategic goals.

Risks

• The value of the granted RSUs and stock options is subject to the future market price fluctuations of CytomX Therapeutics' common stock.
• Vesting of both RSUs and stock options is contingent upon the reporting person's continued service to the Issuer, meaning unvested portions could be forfeited if employment ceases.
• Stock options carry the risk that if the stock price does not rise above the exercise price of $6.09, they may expire worthless.

Future Outlook

The vesting schedules for both the RSUs and stock options extend several years into the future, indicating an expectation of continued service from the Chief Medical Officer and a long-term alignment of interests with the company's performance.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units and stock options, are a standard and widely adopted component of executive compensation packages across the biotechnology and pharmaceutical industries. These grants are crucial for attracting, retaining, and incentivizing key scientific and medical talent, aligning their long-term interests with the company's strategic development and shareholder value creation.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages across the biotechnology and pharmaceutical industries. Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals frequently utilize similar RSU and stock option programs to attract, retain, and incentivize key talent, aligning management's interests with long-term shareholder value.
• The specific size of the grant for a Chief Medical Officer at a company of CytomX's stage would typically be benchmarked against peer companies with similar market capitalizations and development pipelines, though specific comparable grant sizes are not detailed in this filing.

Related Party Transactions

• The grant of restricted stock units and stock options to Yu-Waye Chu, the Chief Medical Officer, constitutes a related party transaction as it involves compensation from the issuer to an executive officer. This is a common and disclosed practice in executive compensation.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Medical Officer's interests with shareholder value creation, as the value of the compensation is directly tied to the company's stock performance.
• Employees: This type of executive compensation can signal stability in leadership and a commitment to long-term strategy, potentially impacting employee morale and retention.

Next Steps

• Continued vesting of 75,000 Restricted Stock Units annually on March 15, starting March 15, 2027, subject to continued service.
• Continued monthly vesting of 300,000 Stock Options from February 2, 2026, leading to full vesting on February 2, 2030, subject to continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation grant and does not contain information that would fundamentally alter the investment thesis for CytomX Therapeutics. While the grant aligns executive interests with shareholders, it is a standard operational event and not indicative of new financial performance or strategic shifts that would warrant a change in investment recommendation based solely on this filing.

Keywords

CytomX Therapeutics, CTMX, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Equity Grant, Beneficial Ownership